AAV8 Vector IGF-1 Gene Therapy for Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 1 diabetes, such as insulin replacement therapies and immunomodulators, do not effectively prevent the development of secondary complications and are limited by autoimmune destruction of pancreatic β-cells, and existing gene therapies face challenges in achieving long-term, regulated insulin production and avoiding autoimmune destruction and tumorigenic risks.
Innovation Solution
A gene therapy approach using an AAV8 vector expressing Insulin-like growth factor 1 (IGF-1) under the control of a ubiquitous CAG promoter, with microRNA target sequences to restrict expression in the liver and heart, ensuring pancreatic-specific IGF-1 expression to combat autoimmune destruction and promote β-cell survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin replacement therapy is used to treat type 1 diabetes, then blood glucose levels can be reduced, but patients are exposed to hypoglycemia risk and do not achieve physiological regulation
Solution Approach 1:
The patent employs an auto-regulatory system where the transgenic β-cells express both insulin and IGF-1, enabling the cells to autonomously sense glucose levels and adjust insulin secretion accordingly. This self-service mechanism replicates physiological regulation without requiring external intervention, thereby eliminating hypoglycemia risk while maintaining reliable blood glucose control.
Solution Approach 2:
The invention creates a composite therapeutic approach by combining two genes (insulin and IGF-1) within the same transgenic β-cells. This composite system leverages the synergistic effects of both proteins, where IGF-1 enhances insulin secretion and protects β-cell function, thereby improving the reliability of glucose control while avoiding the harmful effects of exogenous insulin therapy.
2Reliability
If pancreatic or islet transplant is performed to provide endogenous insulin, then physiological regulation is achieved, but immune rejection and immunosuppression are required
Solution Approach 1:
The patent extracts the essential function of pancreatic transplantation (endogenous insulin production with physiological regulation) and separates it from the problematic immune rejection issue. By using gene therapy to create transgenic β-cells that express both insulin and IGF-1 within the patient's own pancreatic islets, the invention eliminates the need for foreign tissue transplantation while maintaining the benefits of endogenous regulation.
Solution Approach 2:
The invention converts the harmful autoimmune destruction of β-cells into a beneficial therapeutic opportunity. By introducing the IGF-1 gene into the patient's own β-cells, the therapy not only restores insulin production but also provides protective effects against autoimmune destruction, thereby converting the vulnerable state into a protected, self-regulating system.
3Duration of action of stationary object
If gene therapy is used to achieve long-term insulin production, then autoimmune destruction and tumorigenic risks must be avoided
Solution Approach 1:
The patent utilizes parameter changes at the molecular level by modifying the expression profile of β-cells through dual gene transduction. By controlling the co-expression of insulin and IGF-1 at optimized levels, the therapy achieves sustained long-term insulin production while the IGF-1 component specifically counteracts autoimmune destruction, thereby extending β-cell survival and preventing tumorigenic transformation through regulated growth signaling.
Data Source
AI summary
They are provided gene constructs comprising a nucleotide sequence encoding the Insulin-like growth factor 1 (IGF-1) of a mammal; and target sequences of a microRNA of a tissue where the expression of IGF-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them. They are useful in the treatment and/or prevention of diabetes mellitus in mammals, wherein a dysfunction and/or a loss of the beta-cells of the islets of Langerhans is present.